VORAXAZE
Peakglucarpidase
BLAINJECTIONINJECTABLEPriority Review
Approved
Jan 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VORAXAZE (glucarpidase) is a recombinant carboxypeptidase enzyme administered by injection that rapidly inactivates methotrexate and its metabolites. It is indicated for patients experiencing methotrexate toxicity, particularly those with delayed methotrexate clearance due to renal impairment. The drug works by cleaving terminal glutamate residues from methotrexate, converting it to inactive metabolites.
Peak
Product is in peak commercial phase with moderate competitive pressure (30/100), suggesting stable but not growth-oriented team dynamics and focused efficiency-driven operations.
Mechanism of Action
Pharmacologic Class:
Carboxypeptidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
Started Mar 2019
12 enrolled
Osteosarcoma
Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL
Started Jul 2008
47 enrolled
Acute Lymphoblastic Leukemia (ALL)
Career Relevance
VORAXAZE is a niche oncology rescue product with stable but limited career growth, offering roles primarily in commercial execution and medical affairs support rather than innovation or expansion. The product's peak-phase status and specialized indication create focused, specialized teams with deep expertise in a critical but narrow clinical need.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.